BioCentury
ARTICLE | Clinical News

ATX-MS-1467: Phase I data

September 9, 2013 7:00 AM UTC

An open-label, international Phase I trial in 43 patients with relapsing MS showed that 5 dose levels of intradermal ATX-MS-1467 every 2 weeks for 16 weeks led to a significant reduction in the number...